ABG-WTT Global Life Science Capital Partners GP Ltd — 13F Portfolio

ABG-WTT Global Life Science Capital Partners GP Ltd is a general partner and investment management entity dedicated to life sciences–focused private equity and growth-stage venture investing. The vehicle acts as a sponsor and manager for pooled investment funds that back healthcare and life sciences businesses globally, with a particular emphasis on biotechnology, pharmaceuticals, medical technology, and life science tools. The firm appears in the U.S. regulatory system as an institutional investment manager and files Form 13F with the Securities and Exchange Commission under CIK #1832108. This filing status reflects discretionary control over reportable U.S.-listed equities and equity-like securities held within its funds. These positions are generally associated with later-stage, crossover, and post-IPO investments in portfolio companies or closely related opportunities in the listed markets, rather than with a traditional, broad-based public-equity product. Like many specialist life sciences sponsors, ABG-WTT Global Life Science Capital Partners GP Ltd operates across both private and public markets. The majority of its capital is typically deployed in private rounds, structured financings, and follow-on investments; the public sleeve becomes visible when portfolio companies list on U.S. exchanges or when the manager selectively initiates or maintains positions in existing public issuers that fit its thematic focus. On an analytics platform, all Form 13F submissions under CIK #1832108 can be aggregated into a continuous 13F History, providing a time-series record of the manager’s disclosed U.S.-listed holdings. This data set gives allocators an independent lens on how the firm’s life sciences theses have been expressed in listed securities over time.

ABG-WTT Global Life Science Capital Partners GP Ltd pursues a fundamentally driven, long-term strategy concentrated in life sciences. The mandate spans: - Growth and expansion capital for biotechnology and pharmaceutical companies developing novel therapeutics, platforms, and modalities; - Investments in medical device and diagnostics businesses with differentiated technology, clinical utility, or procedure-changing potential; - Life science tools, services, and enabling technologies that support drug discovery, development, and manufacturing across the industry. The investment process emphasizes deep scientific and clinical diligence alongside commercial and regulatory analysis. Typical considerations include: - Strength and defensibility of the scientific platform or technology; - Clinical development plans, regulatory pathways, and competitive landscape; - Capital requirements, balance sheet structure, and prospective financing risk; - Management and sponsor alignment, governance, and exit pathways. Within this framework, the U.S.-listed positions reported in Form 13F generally fall into three categories: 1. Shares in portfolio companies that have completed U.S. IPOs or uplistings and remain core holdings as the value-creation thesis continues post-listing. 2. Strategic or thematic positions in public life sciences issuers that complement the firm’s private portfolio or express specific therapeutic or modality themes. 3. Occasional exposure via sector ETFs or listed vehicles that provide targeted access to subsectors (for example, small- and mid-cap biotech) for liquidity or tactical reasons. As a result, the 13F portfolio is typically concentrated in a limited number of life sciences names rather than diversified across the full breadth of the equity market. A holdings-based review of the manager’s 13F Portfolio Composition over multiple quarters allows allocators to see which therapeutic areas (e.g., oncology, immunology, rare diseases, gene and cell therapy) and business models (platform companies vs. single-asset developers, tools vs. therapeutics) have been persistent focus areas, as well as the degree of single-name and modality concentration. When this 13F history is fed into a Portfolio Simulator or Backtesting Service, it can be translated into a long-only historical replication of the disclosed U.S.-listed sleeve. That reconstructed capital path offers a data-grounded perspective on how the firm’s public life sciences positions would have evolved if held between filing dates, separate from the larger, illiquid private book.

ABG-WTT Global Life Science Capital Partners GP Ltd sits within the 13F universe as a specialist life sciences GP whose public-market footprint reflects a concentrated set of crossover and post-IPO holdings. Filing under CIK #1832108, the firm provides a recurring, position-level record of its U.S.-listed life sciences exposures, even as most of its capital is deployed in private and structured transactions beyond the scope of Form 13F. By aggregating these filings into a unified dataset, an analytics platform can construct a 13F-based Historical Track Record that mirrors a portfolio holding the fund’s disclosed positions between quarter-ends. Examining the behavior of this reconstructed capital trajectory alongside changes in 13F Portfolio Composition—issuer concentration, therapeutic and modality mix, and the timing of entries and exits—helps allocators understand how the public component of the strategy has navigated sector cycles, regulatory regimes, and broader equity markets. Overlaying diagnostics such as Max Drawdown Depth and a holdings-derived Sharpe Ratio adds quantitative depth on the variability and risk-adjusted character of the 13F-implied long-equity stream. Used in conjunction with a Portfolio Simulator and related Performance Backtests Online, these tools provide an independent, public-data-driven lens on one important facet of a broader life sciences private equity and growth investing platform. The key open question for allocators is how sensitive this 13F-visible crossover sleeve is to different market and policy regimes—biotech bull and bear phases, changes in funding conditions, and shifts in regulatory or reimbursement sentiment—and how that regime sensitivity interacts with, or differs from, the behavior of the firm’s larger, less liquid private portfolios across the same periods.

The risk profile of ABG-WTT Global Life Science Capital Partners GP Ltd’s strategy is characteristic of specialized life sciences investors combining private and crossover/public exposure. At the asset level, key drivers of risk include: - Scientific and clinical trial risk, often with binary or highly asymmetric outcomes around key data readouts and regulatory decisions; - Financing and dilution risk, particularly for pre-revenue biotech companies reliant on capital markets to fund development; - Regulatory and reimbursement risk that can affect entire therapeutic categories or modalities; - Elevated idiosyncratic volatility, as news flow on individual programs or safety signals can produce large price moves. Through the narrower lens of Form 13F, only the long U.S.-listed equity and equity-like positions are visible. From this perspective, observable risk characteristics include: - Concentration in a relatively small number of life sciences issuers, creating meaningful single-name and sector exposure; - High volatility relative to broad equity benchmarks, given the developmental nature of many holdings; - Style and factor tilts typical of biotech and medtech portfolios, such as growth orientation, smaller and mid-cap capitalization, and low current earnings. By treating each 13F filing as a quarter-end snapshot and running Performance Backtests Online, an allocator can construct a synthetic, long-only capital path that holds the fund’s disclosed positions between reporting dates. From this reconstructed stream, it is possible to estimate overall volatility, beta versus healthcare and broad equity indices, and downside behavior during sector and market drawdowns. Metrics such as Max Drawdown Depth summarize the most severe peak-to-trough contractions implied by the 13F-based replication, while a holdings-derived Sharpe Ratio provides a concise measure of risk-adjusted outcomes for this long-equity sleeve. These analytics must be interpreted with structural caveats. Form 13F does not capture the firm’s private investments, structured financings, or any hedging and derivative activity, nor does it reveal intra-quarter trading. Consequently, the volatility and drawdown statistics derived from 13F-based replication describe only an unhedged, listed-equity fragment of ABG-WTT Global Life Science Capital Partners GP Ltd’s overall exposure, not the complete economic risk profile of its funds.